GILDKite, A Gilead CompanyFinished
A Study of Axicabtagene Ciloleucel in Participants With Relapsed/Refractory Indolent Non-Hodgkin Lymphoma
Follicular Lymphoma · Marginal Zone Lymphoma · Indolent Non-Hodgkin Lymphoma
0Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 2
- Patients
- 159 (final count)
- Started
- Jun 6, 2017
- Main results expected
- Dec 20, 2024
- Fully finished
- Dec 20, 2024
- Results posted
- Dec 23, 2025
What counts as success
The trial's main goal(s), called the “primary outcome.”
Objective Response Rate (ORR): Percentage of Participants With Objective Response Per the Lugano Classification by Central Assessment
Measured over: Up to 85.6 months
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT03105336 · record last updated 2025-12-23 · checked 2026-11-09 15:47 UTC